31 results on '"Chanona-Vilchis J"'
Search Results
2. Throat clearing as the only symptom of eosinophilic esophagitis: A case report
- Author
-
Rojas Pineda, N.A., primary, Morfin Maciel, B.M., additional, and Chanona-Vilchis, J., additional
- Published
- 2020
- Full Text
- View/download PDF
3. Carcinosarcoma of the Pancreas Arising in a Mucinous Cystic Neoplasm
- Author
-
Mark Bloomston, Ramirez Nc, E. C. Ellison, Chanona-Vilchis J, and Wendy L. Frankel
- Subjects
Pancreatic duct ,Pathology ,medicine.medical_specialty ,Common bile duct ,business.industry ,General Medicine ,medicine.disease ,Cystic Neoplasm ,Cytokeratin ,medicine.anatomical_structure ,Carcinosarcoma ,medicine ,Mucinous cystadenocarcinoma ,Pancreas ,business ,Spindle cell carcinoma - Abstract
We report a carcinosarcoma of the pancreas in a 67-year-old woman who presented with nausea, vomiting, and painless jaundice. A work-up demonstrated a well-circumscribed mass in the head of the pancreas. After pylorus-preserving pancreaticoduodenectomy, the tumor was found to be grossly yellow, and it compressed the common bile duct and pancreatic duct. Histological examination of the neoplasm showed a 4.0 x 4.0 x 3.0-cm mucinous cystadenocarcinoma with invasive poorly differentiated carcinoma, well-differentiated squamous cell carcinoma, and sarcomatous stroma invading into the duodenum. There was no evidence of nodal metastasis (pT3N0M0). Immunohistochemical studies showed that the epithelial cells stained positive for cytokeratin 7, cytokeratin AE1/3, cytokeratin monoclonal antibody 5.2, epithelial membrane antigen, M-carcinoembryonic antigen, and low-molecular-weight kininogen, and the sarcomatous component was immunoreactive with vimentin. The patient had an uneventful recovery, but died 4 months later of rapidly progressive metastatic disease to the liver and peritoneum. To the best of our knowledge, this is the second case of carcinosarcoma with invasive epithelial and sarcomatous areas in the background of a mucinous cystic neoplasm of the pancreas.
- Published
- 2006
4. Zygomycosis in Two Hematologic Cases
- Author
-
García-Romero, M. T., García-Méndez, J., Arenas, R., Ferrari-Carballo, T., Chanona-Vilchis, J., and Cervera-Ceballos, E.
- Subjects
Article Subject - Abstract
Zygomycosis are invasive mould infections, rarely diagnosed in hematologic patients. Most of the cases published are in patients with prolonged neutropenia, along with other risk factors such as the use of prior broad-spectrum antibiotics (including new antifungal agents, such as voriconazole), diabetes mellitus (with or without ketoacidosis), malnutrition, iron overload (with or without the use of deferoxamine). These infections have poor prognosis due to the involvement of vital anatomic structures and late diagnosis. Until recent years, the treatment was based on high doses of amphotericin B plus surgical debridement. Here we present two patients with hematologic diseases (one with leukemia, the second with aplastic anemia) with an impaired immune system and the diagnosis of zygomycosis. The survival of one of them was mainly due to early diagnosis and surgical debridement; unfortunately the second was misdiagnosed as an extensive ecchymosis due to thrombocytopenia and died with CNS involvement.
- Published
- 2011
- Full Text
- View/download PDF
5. Endocervical adenocarcinoma — Proposal for a new histopathologic pattern-based classification system with significant clinical implications: A multi-institutional study
- Author
-
Rutgers, J., primary, Jordan, S., additional, Park, K., additional, Alvarado-Cabrero, I., additional, Rasty, G., additional, Hong, S., additional, Chanona-Vilchis, J., additional, De Vivar, A., additional, Arville, B., additional, Barbuto, D., additional, Roma, A., additional, Ali-Fehmi, R., additional, Tabassum, F., additional, Teramoto, N., additional, Mikami, Y., additional, and Silva, E., additional
- Published
- 2012
- Full Text
- View/download PDF
6. Classifying endocervical adenocarcinoma (EADC) by pattern correlates better with the presence or absence of lymph node (LN) metastasis than using tumor depth of invasion
- Author
-
Alvarado-Cabrero, I., primary, Park, K., additional, Rasty, G., additional, Hong, S., additional, Chanona-Vilchis, J., additional, Diaz De Vivar, A., additional, Barbuto, D., additional, Roma, A., additional, Ali-Fehmi, R., additional, and Silva, E., additional
- Published
- 2012
- Full Text
- View/download PDF
7. Primary malignant lymphoma of uterine cervix
- Author
-
CANTU DE LEON, D., primary, PEREZ MONTIEL, D., additional, and CHANONA VILCHIS, J., additional
- Published
- 2006
- Full Text
- View/download PDF
8. The Third National Ovarian Cancer Consensus 2011. Grupo de Investigacion en Cancer de Ovario y Tumores Ginecologicos de Mexico 'GICOM' | Tercer Consenso Nacional de Cáncer de Ovario 2011. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México 'GICOM'
- Author
-
Gallardo-Rincón, D., David Cantu-de Leon, Alanís-López, P., Álvarez-Avitia, M. Á, Bañuelos-Flores, J., Herbert-Núñez, G. S., Oñate-Ocaña, L. F., Pérez-Montiel, M. D., Rodríguez-Trejo, A., Ruvalcaba-Limón, E., Serrano-Olvera, A., Ortega-Rojo, A., Cortés-Esteban, P., Erazo-Valle, A., Gerson-Cwilich, R., De-La-Garza-Salazar, J., Green-Renner, D., León-Rodríguez, E., Morales-Vásquez, F., Poveda-Velasco, A., Aguilar-Ponce, J. L., Alva-López, L. F., Alvarado-Aguilar, S., Alvarado-Cabrero, I., Aquino-Mendoza, C. A., Aranda-Flores, C. E., Bandera-Delgado, A., Barragán-Curiel, E., Barrón-Rodríguez, P., Brom-Valladares, R., Cabrera-Galeana, P. A., Calderillo-Ruiz, G., Camacho-Gutiérrez, S., Capdeville-García, D., Cárdenas-Sánchez, J., Carlón-Zárate, E., Carrillo-Garibaldi, Ó, Castorena-Roji, G., Cervantes-Sánchez, G., Coronel-Martínez, J. A., Chanona-Vilchis, J. G., Díaz-Hernández, V., Escudero-De-Los Ríos, P., Garibay-Cerdenares, O., Gómez-García, E., Herrera-Montalvo, L. A., Hinojosa-García, L. M., Isla-Ortiz, D., Jiménez-López, J., Lavín-Lozano, A. J., Limón-Rodríguez, J. A., López-Basave, H. N., López-García, S. C., Maffuz-Aziz, A., Martínez-Cedillo, J., Martínez-López, D. M., Medina-Castro, J. M., Melo-Martínez, C., Méndez-Herrera, C., Montalvo-Esquivel, G., Morales-Palomares, M. Á, Morán-Mendoza, A., Morgan-Villela, G., Mota-García, A., Muñoz-González, D. E., Ochoa-Carrillo, F. J., Pérez-Amador, M., Recinos-Money, E., Rivera-Rivera, S., Robles Flores, J. U., Rojas-Castillo, E., Rojas-Marín, C., Salas-Gonzáles, E., Sámano-Nateras, L., Santibañez-Andrade, M., Santillán-Gómez, A., Silva-García, A., Silva, J. A., Solorza-Luna, G., Tabarez-Ortiz, A. R., Talamás-Rohana, P., Tirado-Gómez, L. L., Torres-Lobatón, A., and Quijano-Castro, F.
9. The Third National Ovarian Cancer Consensus 2011. Grupo de Investigacion en Cancer de Ovario y Tumores Ginecologicos de Mexico 'GICOM',Tercer Consenso Nacional de Cáncer de Ovario 2011. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México 'GICOM'
- Author
-
Gallardo-Rincón, D., Cantú-De-León, D., Alanís-López, P., Álvarez-Avitia, M. Á, Bañuelos-Flores, J., Herbert-Núñez, G. S., Oñate-Ocaña, L. F., Pérez-Montiel, M. D., Rodríguez-Trejo, A., Ruvalcaba-Limón, E., Serrano-Olvera, A., Ortega-Rojo, A., Cortés-Esteban, P., Erazo-Valle, A., Gerson-Cwilich, R., De-La-Garza-Salazar, J., Green-Renner, D., León-Rodríguez, E., Morales-Vásquez, F., Poveda-Velasco, A., Aguilar-Ponce, J. L., Alva-López, L. F., Alvarado-Aguilar, S., Alvarado-Cabrero, I., Aquino-Mendoza, C. A., Aranda-Flores, C. E., Bandera-Delgado, A., Barragán-Curiel, E., Barrón-Rodríguez, P., Brom-Valladares, R., Cabrera-Galeana, P. A., Calderillo-Ruiz, G., Camacho-Gutiérrez, S., Capdeville-García, D., Cárdenas-Sánchez, J., Carlón-Zárate, E., Carrillo-Garibaldi, Ó, Castorena-Roji, G., Cervantes-Sánchez, G., Coronel-Martínez, J. A., Chanona-Vilchis, J. G., Díaz-Hernández, V., Escudero-De-Los Ríos, P., Garibay-Cerdenares, O., Gómez-García, E., Herrera-Montalvo, L. A., Hinojosa-García, L. M., Isla-Ortiz, D., Jiménez-López, J., Lavín-Lozano, A. J., Limón-Rodríguez, J. A., López-Basave, H. N., López-García, S. C., Maffuz-Aziz, A., Martínez-Cedillo, J., Martínez-López, D. M., Medina-Castro, J. M., Melo-Martínez, C., Méndez-Herrera, C., Montalvo-Esquivel, G., Morales-Palomares, M. Á, Morán-Mendoza, A., Morgan-Villela, G., Mota-García, A., Muñoz-González, D. E., Ochoa-Carrillo, F. J., Pérez-Amador, M., Recinos-Money, E., Rivera-Rivera, S., Robles Flores, J. U., Rojas-Castillo, E., Rojas-Marín, C., Salas-Gonzáles, E., Sámano-Nateras, L., Santibañez-Andrade, M., Santillán-Gómez, A., Silva-García, A., Silva, J. A., Solorza-Luna, G., Tabarez-Ortiz, A. R., Patricia Talamás-Rohana, Tirado-Gómez, L. L., Torres-Lobatón, A., and Quijano-Castro, F.
10. Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors
- Author
-
Avilés-Salas Alejandro, Villarreal-Garza Cynthia, Ángeles-Sánchez Julián, Michel Ortega Rosa, Arrieta Oscar, Chanona-Vilchis José G, Aréchaga-Ocampo Elena, Luévano-González Arturo, Jiménez Miguel, and Aguilar José
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Germ cell testicular tumors have survival rate that diminishes with high tumor marker levels, such as human chorionic gonadotropin (hCG). hCG may regulate vascular neoformation through vascular endothelial growth factor (VEGF). Our purpose was to determine the relationship between hCG serum levels, angiogenesis, and VEGF expression in germ cell testicular tumors. Methods We conducted a retrospective study of 101 patients. Serum levels of hCG, alpha-fetoprotein (AFP), and lactate dehydrogenase were measured prior to surgery. Vascular density (VD) and VEGF tissue expression were determined by immunohistochemistry and underwent double-blind analysis. Results Histologically, 46% were seminomas and 54%, non-seminomas. Median follow-up was 43 ± 27 months. Relapse was present in 7.5% and mortality in 11.5%. Factors associated with high VD included non-seminoma type (p = 0.016), AFP ≥ 14.7 ng/mL (p = 0.0001), and hCG ≥ 25 mIU/mL (p = 0.0001). In multivariate analysis, the only significant VD-associated factor was hCG level (p = 0.04). When hCG levels were stratified, concentrations ≥ 25 mIU/mL were related with increased neovascularization (p < 0.0001). VEGF expression was not associated with VD or hCG serum levels. Conclusion This is the first study that relates increased serum hCG levels with vascularization in testicular germ cell tumors. Hence, its expression might play a role in tumor angiogenesis, independent of VEGF expression, and may explain its association with poor prognosis. hCG might represent a molecular target for therapy.
- Published
- 2009
- Full Text
- View/download PDF
11. Use of an orthovoltage X-ray treatment unit as a radiation research system in a small-animal cancer model
- Author
-
Jurado Rafael, García-López Patricia, Castro-Morales Mario-Alberto, Herrera-Penilla Blanca-Ivone, Medina Luis-Alberto, Pérez-Cárdenas Enrique, Chanona-Vilchis José, and Brandan María-Ester
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background We explore the use of a clinical orthovoltage X-ray treatment unit as a small-animal radiation therapy system in a tumoral model of cervical cancer. Methods Nude mice were subcutaneously inoculated with 5 × 106 HeLa cells in both lower limbs. When tumor volume approximated 200 mm3 treatment was initiated. Animals received four 2 mg/kg intraperitoneal cycles (1/week) of cisplatin and/or 6.25 mg/kg of gemcitabine, concomitant with radiotherapy. Tumors were exposed to 2.5 Gy/day nominal surface doses (20 days) of 150 kV X-rays. Lead collimators with circular apertures (0.5 to 1.5 cm diameter) were manufactured and mounted on the applicator cone to restrict the X-ray beam onto tumors. X-ray penetration and conformality were evaluated by measuring dose at the surface and behind the tumor lobe by using HS GafChromic film. Relative changes in tumor volume (RTV) and a clonogenic assay were used to evaluate the therapeutic response of the tumor, and relative weight loss was used to assess toxicity of the treatments. Results No measurable dose was delivered outside of the collimator apertures. The analysis suggests that dose inhomogeneities in the tumor reach up to ± 11.5% around the mean tumor dose value, which was estimated as 2.2 Gy/day. Evaluation of the RTV showed a significant reduction of the tumor volume as consequence of the chemoradiotherapy treatment; results also show that toxicity was well tolerated by the animals. Conclusion Results and procedures described in the present work have shown the usefulness and convenience of the orthovoltage X-ray system for animal model radiotherapy protocols.
- Published
- 2008
- Full Text
- View/download PDF
12. Primary retroperitoneal mucinous cystadenocarcinoma: report of two cases
- Author
-
Villavicencio-Valencia Verónica, Dueñas-González Alfonso, Chanona-Vilchis José, Pérez-Montiel Delia, de León David, and Zavala-Casas Gladys
- Subjects
Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Retroperitoneal cystadenocarcinomas are rare lesions, the majority of cases presented as one-patient reports. Methods We present two cases of retroperitoneal cystadenocarcinoma, both in women of reproductive age: one with aggressive behavior, and the remaining case, with a more indolent clinical evolution. Results One case presented as pelvic tumor, was treated with surgical resection of the disease, but manifested with recurrent disease a few months later despite use of chemotherapy. The second case involved a patient with diagnosis of abdominal tumor; during laparotomy, a retroperitoneal tumor was found and was totally removed. At follow-up, the patient is disease-free with no other treatment. Conclusion The behavior and treatment of retroperitoneal cystadenocarcinoma are controversial. We suggest aggressive surgery including radical hysterectomy and bilateral salpingoopherectomy with adjuvant chemotherapy in these cases.
- Published
- 2007
- Full Text
- View/download PDF
13. Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
- Author
-
Robles Elizabeth, Chanona-Vilchis Jose, Candelaria Myrna, Martínez-Tlahuel Jorge, González-Fierro Aurora, Chavez-Blanco Alma, Taja-Chayeb Lucia, and Dueñas-Gonzalez Alfonso
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract Background Despite significant achievements in the treatment of cervical cancer, it is still a deadly disease; hence newer therapeutical modalities are needed. Preliminary investigations suggest that platelet-derived growth factor (PDGF) might have a role in the development of cervical cancer, therefore it is important to determine whether this growth factor pathway is functional and its targeting with imatinib mesylate leads to growth inhibition of cervical cancer cells. Results PDGF receptors (PDGFR) and their ligands are frequently expressed in cervical cancer and the majority exhibited a combination of family members co-expression. A number of intronic and exonic variations but no known mutations in the coding sequence of the PDGFRα gene were found in cancer cell lines and primary tumors. Growth assays demonstrated that PDGFBB induces growth stimulation that can be blocked by imatinib and that this tyrosine kinase inhibitor on its own inhibits cell growth. These effects were associated with the phosphorylation status of the receptor. Conclusion The PDGFR system may have a role in the pathogenesis of cervical cancer as their members are frequently expressed in this tumor and cervical cancer lines are growth inhibited by the PDGFR antagonist imatinib.
- Published
- 2006
- Full Text
- View/download PDF
14. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
- Author
-
Trejo-Becerril Catalina, Sandoval Karina, Cabrera Gustavo, Angeles Enrique, Chavez-Blanco Alma, Taja-Chayeb Lucía, Revilla-Vazquez Alma, Cetina Lucely, Perez-Cardenas Enrique, Segura-Pacheco Blanca, Zambrano Pilar, Chanona-Vilchis Jose, and Duenas-González Alfonso
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The antihypertensive compound hydralazine is a known demethylating agent. This phase I study evaluated the tolerability and its effects upon DNA methylation and gene reactivation in patients with untreated cervical cancer. Methods Hydralazine was administered to cohorts of 4 patients at the following dose levels: I) 50 mg/day, II) 75 mg/day, III) 100 mg/day and IV) 150 mg/day. Tumor biopsies and peripheral blood samples were taken the day before and after treatment. The genes APC, MGMT; ER, GSTP1, DAPK, RARβ, FHIT and p16 were evaluated pre and post-treatment for DNA promoter methylation and gene expression by MSP (Methylation-Specific PCR) and RT-PCR respectively in each of the tumor samples. Methylation of the imprinted H19 gene and the "normally methylated" sequence clone 1.2 was also analyzed. Global DNA methylation was analyzed by capillary electrophoresis and cytosine extension assay. Toxicity was evaluated using the NCI Common Toxicity Criteria. Results Hydralazine was well tolerated. Toxicities were mild being the most common nausea, dizziness, fatigue, headache and palpitations. Overall, 70% of the pretreatment samples and all the patients had at least one methylated gene. Rates of demethylation at the different dose levels were as follows: 50 mg/day, 40%; 75 mg/day, 52%, 100 mg/day, 43%, and 150 mg/day, 32%. Gene expression analysis showed only 12 informative cases, of these 9 (75%) re-expressed the gene. There was neither change in the methylation status of H19 and clone 1.2 nor changes in global DNA methylation. Conclusion Hydralazine at doses between 50 and 150 mg/day is well tolerated and effective to demethylate and reactivate the expression of tumor suppressor genes without affecting global DNA methylation
- Published
- 2005
- Full Text
- View/download PDF
15. Zygomycosis in Two Hematologic Cases
- Author
-
T. García-Romero, M., García-Méndez, J., Arenas, R., Ferrari-Carballo, T., Chanona-Vilchis, J., and Cervera-Ceballos, E.
- Abstract
Zygomycosis are invasive mould infections, rarely diagnosed in hematologic patients. Most of the cases published are in patients with prolonged neutropenia, along with other risk factors such as the use of prior broad-spectrum antibiotics (including new antifungal agents, such as voriconazole), diabetes mellitus (with or without ketoacidosis), malnutrition, iron overload (with or without the use of deferoxamine). These infections have poor prognosis due to the involvement of vital anatomic structures and late diagnosis. Until recent years, the treatment was based on high doses of amphotericin B plus surgical debridement. Here we present two patients with hematologic diseases (one with leukemia, the second with aplastic anemia) with an impaired immune system and the diagnosis of zygomycosis. The survival of one of them was mainly due to early diagnosis and surgical debridement; unfortunately the second was misdiagnosed as an extensive ecchymosis due to thrombocytopenia and died with CNS involvement.
- Published
- 2011
- Full Text
- View/download PDF
16. Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells.
- Author
-
Pérez-Cárdenas E, Taja-Chayeb L, Trejo-Becerril C, Chanona-Vilchis J, Chávez-Blanco A, Domínguez-Gómez G, Langley E, García-Carrancá A, and Dueñas-González A
- Abstract
Introduction: Metastasis involves the accumulation of genetic and epigenetic alterations leading to activation of prometastatic genes and inactivation of antimetastatic genes. Among epigenetic alterations, DNA hypermethylation and histone hypoacetylation are the focus of intense translational research because their pharmacological inhibition has been shown to produce antineoplastic activity in a variety of experimental models., Aims: This study aimed to evaluate the antimetastatic effect of the DNA-methylation inhibitor, hydralazine, and the histone deacetylase inhibitor, valproic acid., Methods: NIH 3T3- Ras murine cells were treated with hydralazine and valproic acid to evaluate their effects upon cell proliferation, cell motility, chemotaxis, gelatinase activity, and gene expression. Lung metastases were developed by intravenous injection of NIH 3T3- Ras cells in BALB/c nu/nu mice and then treated with the drug combination., Results: Treatment induced a growth-inhibitory effect on NIH 3T3- Ras cells, showed a trend toward increased gelatinase activity of MMP2 and MMP9, and inhibited chemotaxis and cell motility. The combination led to a strong antimetastatic effect in lungs of nude mice., Conclusion: Hydralazine and valproic acid, two repositioned drugs as epigenetic agents, exhibit antimetastatic effects in vitro and in vivo and hold potential for cancer treatment., Competing Interests: Disclosure The authors report no conflicts of interest in this work.
- Published
- 2018
- Full Text
- View/download PDF
17. [A woman with a pure seminoma and a contralateral intratubular germinal neoplasm. A case report].
- Author
-
Herrera-Gómez Á, García-Pérez L, Gallardo-Alvarado L, Isla-Ortiz D, Salcedo-Hernández RA, and Chanona-Vilchis J
- Subjects
- Androgen-Insensitivity Syndrome blood, Androgen-Insensitivity Syndrome diagnosis, Biomarkers, Tumor blood, Chorionic Gonadotropin blood, Delayed Diagnosis, Diagnostic Errors, Dysgerminoma diagnosis, Early Detection of Cancer, Female, Hernia, Inguinal complications, Humans, Luteinizing Hormone blood, Magnetic Resonance Imaging, Male, Ovarian Neoplasms diagnosis, Seminoma blood, Seminoma etiology, Testicular Neoplasms blood, Testicular Neoplasms etiology, Testosterone blood, Androgen-Insensitivity Syndrome complications, Cryptorchidism complications, Gonadal Dysgenesis, 46,XY complications, Neoplasms, Multiple Primary diagnosis, Seminoma diagnosis, Testicular Neoplasms diagnosis
- Abstract
Background: Androgen insensitivity syndrome is an X-linked disorder, and is characterised by a female phenotype in a chromosomally male individual. It usually occurs in puberty with primary amenorrhoea or as an inguinal tumour in a female infant. In recent years, it is often also diagnosed in fertility clinics in adulthood., Objective: The case is presented of a pure seminoma in a woman with the reference diagnosis of inguinal hernia., Clinical Case: A 53 year old woman, who was operated on in 2014 due to a nodule in left groin. Androgen insensitivity syndrome was corroborated, and histopathology reported it as a right testicular seminoma., Discussion: The importance of early diagnosis is discussed, highlighting the consequences of misdiagnosis, and question whether these patients have been adequately treated in the past. The risk of malignant transformation of an undescended testicle increases with age, thus gonadectomy should be performed after puberty, and in some cases hormone replacement therapy., (Copyright © 2016 Academia Mexicana de Cirugía A.C. Publicado por Masson Doyma México S.A. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
18. Vascular invasion in uterine sarcomas and its significance. A multi-institutional study.
- Author
-
Roma AA, Barbuto DA, Samimi SA, Stolnicu S, Alvarado-Cabrero I, Chanona-Vilchis J, Aguilera-Barrantes I, de Peralta-Venturina M, Malpica A, Rutgers JK, and Silva EG
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Neoplasm Recurrence, Local pathology, Sarcoma, Endometrial Stromal pathology, Endometrial Neoplasms pathology, Neovascularization, Pathologic pathology, Sarcoma pathology, Uterine Neoplasms pathology
- Abstract
Although metastases and high-mortality are frequent in high-grade endometrial sarcomas (HGSs), these findings are less commonly seen in low-grade endometrial stromal sarcomas (LGESSs), even in cases with lymphovascular invasion (LVI). We hypothesized that the "bulging plugs" of tumor characteristic of LVI in LGESS are fundamentally different from LVI seen in HGS. We reviewed 70 uterine sarcomas: 42 HGSs (high-grade endometrial stromal sarcomas, undifferentiated uterine sarcoma, and leiomyosarcoma) and 28 LGESSs. All cases had LVI documented on the histologic slides. Immunostains for CD31, ERG, and D2-40 were performed. LGESS harbored cohesive intravascular tumor foci with direct communication from the main tumor and attached to the vessel wall. The intravascular foci included tumor cells and small arteriole-type vessels and were surrounded by a thin fibrous band. Vascular markers confirmed the LVI and highlighted positively stained endothelial cells separating intravascular tumor foci from the blood itself. In contrast, intravascular tumor foci in HGS were composed of discohesive cells clusters, lacking the features described in LGESS. Only 8 (30.8%) patients with LGESS had recurrence/metastases (6 with lung metastasis); only 1 patient died of disease. Thirty (77%) patients with HGS had recurrence/metastases, 27 (69%) patients had lung metastases, and 22 (56.4%) patients died of disease. We propose that in most LGESSs, LVI represents vascular intrusion; manipulation or trauma is potentially responsible for tumor cell detachment into the circulation increasing the chances of recurrence/metastases. Classic LVI features were identified in HGS. This important distinction may allow for better management of patients and avoid unnecessary treatment in LGESS, reducing morbidity., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
19. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
- Author
-
Perez Montiel D, Arispe Angulo K, Cantú-de León D, Bornstein Quevedo L, Chanona Vilchis J, and Herrera Montalvo L
- Subjects
- Adenocarcinoma, Mucinous metabolism, Adenocarcinoma, Mucinous pathology, Adult, Aged, CDX2 Transcription Factor, Colonic Neoplasms metabolism, Diagnosis, Differential, Female, Homeodomain Proteins metabolism, Humans, Immunohistochemistry, Keratin-20 metabolism, Middle Aged, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Teratoma pathology, Adenocarcinoma, Mucinous diagnosis, Biomarkers, Tumor metabolism, Colonic Neoplasms diagnosis, Colonic Neoplasms pathology, Matrix Attachment Region Binding Proteins metabolism, Ovarian Neoplasms diagnosis, Ovarian Neoplasms secondary, Transcription Factors metabolism
- Abstract
Primary mucinous adenocarcinomas of the ovary are a diagnostic challenge because their histologic and immunohistochemical features usually overlap with metastatic tumors. SATB2 is a recently identified protein with restricted expression in the glandular cells lining the lower gastrointestinal tract. The aim of this study is to examine the differential expression of SATB2 in primary and metastatic tumors of the ovary. Mucinous ovarian tumors of intestinal type were retrieved from the pathology files of the Instituto Nacional de Cancerología de México. A double reading of the hematoxylin and eosin-stained slides was performed to confirm the diagnosis, and a detailed review of the clinical chart was performed to define the primary origin of the tumor (ovarian vs metastatic). Immunohistochemical staining for CK20, CDX2, and SATB2 was performed and evaluated by 2 gynecopathologists. A total of 106 mucinous tumors were identified, 26 of which were considered to be metastatic, and 80 of which were primary ovarian tumors. All of the primary tumors that were not associated with cystic teratomas were negative for SATB2, and the 4 that were associated with a teratoma were positive for SATB2. All 20 of the metastatic tumors of the colon and appendix were positive for CK20, and 4 were positive for CK7. In addition, all 20 of these tumors were positive for SATB2, and 19 were positive for CDX2. SATB2 appears to be a useful marker for the diagnosis of primary vs metastatic mucinous intestinal-type neoplasms and is highly sensitive in detecting lower gastrointestinal tract metastasis., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
20. Endometrial stromal sarcomas: immunoprofile with emphasis on HMB45 reactivity.
- Author
-
Albores-Saavedra J, Dorantes-Heredia R, Chablé-Montero F, Chanona-Vilchis J, Pérez-Montiel D, Lino-Silva LS, González-Romo MA, Ramírez-Jaramillo JM, and Henson DE
- Subjects
- Adult, Aged, Endometrial Neoplasms mortality, Endometrial Neoplasms pathology, Endometrium metabolism, Endometrium pathology, Female, Humans, Immunohistochemistry, Middle Aged, Sarcoma, Endometrial Stromal mortality, Sarcoma, Endometrial Stromal pathology, Sarcoma, Endometrial Stromal secondary, Stromal Cells metabolism, Stromal Cells pathology, gp100 Melanoma Antigen, Biomarkers, Tumor metabolism, Endometrial Neoplasms metabolism, Melanoma-Specific Antigens metabolism, Sarcoma, Endometrial Stromal metabolism
- Abstract
Objectives: We describe the morphologic and immunohistochemical features of 17 endometrial stromal neoplasms, 16 sarcomas, and one stromal nodule., Methods: We reviewed 35 cases interpreted as endometrial stromal neoplasms, but 17 high-grade endometrial stromal sarcomas (ESS) and one case of mixed endometrial sarcoma and leiomyosarcoma were excluded from the study. Data from the Surveillance Epidemiology and End Results program on low- and high-grade ESS for 1973 through 2003 were obtained., Results: One uterine primary ESS had collections of clear cells (20%), while a metastatic ESS contained predominantly clear cells (90%). CD10 (88.2%) and smooth muscle actin (70.5%) were the most common positive immunohistochemical markers. The latter marker was located in the cytoplasm in 47% of the ESS and in the nucleus in 23.5%, a previously unreported feature. HMB45 was detected in 23.5% of the ESS, which contrasts with the 2% reported by other authors., Conclusions: The presence of clear cells and HMB45 reactivity does not justify the term perivascular epithelioid cell tumors for these neoplasms. Two of 17 patients with ESS died of metastatic disease. However, among 274 cases of ESS (all stages included) collected by the Surveillance Epidemiology and End Results Program of the National Cancer Institute during a 30-year period, the 10-year survival rate was 94%., (Copyright© by the American Society for Clinical Pathology.)
- Published
- 2014
- Full Text
- View/download PDF
21. Use of an orthovoltage X-ray treatment unit as a radiation research system in a small-animal cancer model.
- Author
-
Medina LA, Herrera-Penilla BI, Castro-Morales MA, García-López P, Jurado R, Pérez-Cárdenas E, Chanona-Vilchis J, and Brandan ME
- Subjects
- Animals, Disease Models, Animal, Female, HeLa Cells, Humans, Mice, Mice, Nude, Xenograft Model Antitumor Assays, Uterine Cervical Neoplasms radiotherapy
- Abstract
Background: We explore the use of a clinical orthovoltage X-ray treatment unit as a small-animal radiation therapy system in a tumoral model of cervical cancer., Methods: Nude mice were subcutaneously inoculated with 5 x 106 HeLa cells in both lower limbs. When tumor volume approximated 200 mm3 treatment was initiated. Animals received four 2 mg/kg intraperitoneal cycles (1/week) of cisplatin and/or 6.25 mg/kg of gemcitabine, concomitant with radiotherapy. Tumors were exposed to 2.5 Gy/day nominal surface doses (20 days) of 150 kV X-rays. Lead collimators with circular apertures (0.5 to 1.5 cm diameter) were manufactured and mounted on the applicator cone to restrict the X-ray beam onto tumors. X-ray penetration and conformality were evaluated by measuring dose at the surface and behind the tumor lobe by using HS GafChromic film. Relative changes in tumor volume (RTV) and a clonogenic assay were used to evaluate the therapeutic response of the tumor, and relative weight loss was used to assess toxicity of the treatments., Results: No measurable dose was delivered outside of the collimator apertures. The analysis suggests that dose inhomogeneities in the tumor reach up to +/- 11.5% around the mean tumor dose value, which was estimated as 2.2 Gy/day. Evaluation of the RTV showed a significant reduction of the tumor volume as consequence of the chemoradiotherapy treatment; results also show that toxicity was well tolerated by the animals., Conclusion: Results and procedures described in the present work have shown the usefulness and convenience of the orthovoltage X-ray system for animal model radiotherapy protocols.
- Published
- 2008
- Full Text
- View/download PDF
22. Primary retroperitoneal mucinous cystadenocarcinoma: report of two cases.
- Author
-
de León DC, Pérez-Montiel D, Chanona-Vilchis J, Dueñas-González A, Villavicencio-Valencia V, and Zavala-Casas G
- Subjects
- Adult, Cystadenocarcinoma, Mucinous diagnosis, Female, Humans, Retroperitoneal Neoplasms diagnosis, Young Adult, Cystadenocarcinoma, Mucinous pathology, Retroperitoneal Neoplasms pathology
- Abstract
Background: Retroperitoneal cystadenocarcinomas are rare lesions, the majority of cases presented as one-patient reports., Methods: We present two cases of retroperitoneal cystadenocarcinoma, both in women of reproductive age: one with aggressive behavior, and the remaining case, with a more indolent clinical evolution., Results: One case presented as pelvic tumor, was treated with surgical resection of the disease, but manifested with recurrent disease a few months later despite use of chemotherapy. The second case involved a patient with diagnosis of abdominal tumor; during laparotomy, a retroperitoneal tumor was found and was totally removed. At follow-up, the patient is disease-free with no other treatment., Conclusion: The behavior and treatment of retroperitoneal cystadenocarcinoma are controversial. We suggest aggressive surgery including radical hysterectomy and bilateral salpingoopherectomy with adjuvant chemotherapy in these cases.
- Published
- 2007
- Full Text
- View/download PDF
23. Unusual case of subcutaneous angiosarcoma metastatic to the ovary.
- Author
-
Cantú De León D, Pérez Montiel D, and Chanona Vilchis J
- Subjects
- Adult, Female, Humans, Ovarian Neoplasms diagnosis, Ovarian Neoplasms pathology, Tomography, X-Ray Computed, Hemangiosarcoma pathology, Ovarian Neoplasms secondary, Soft Tissue Neoplasms pathology
- Abstract
The ovaries are common sites for metastatic disease, however, the most frequent ones are carcinomas. Metastatic sarcomas are very rare in ovary and most of them arise from genital tract. We present the case of a 33-year-old woman with subcutaneous angiosarcoma who had metastatic disease to the ovary resulting in acute abdominal pain. Discussion of the case and a review of the literature are presented.
- Published
- 2007
- Full Text
- View/download PDF
24. Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer.
- Author
-
Taja-Chayeb L, Chavez-Blanco A, Martínez-Tlahuel J, González-Fierro A, Candelaria M, Chanona-Vilchis J, Robles E, and Dueñas-Gonzalez A
- Abstract
Background: Despite significant achievements in the treatment of cervical cancer, it is still a deadly disease; hence newer therapeutical modalities are needed. Preliminary investigations suggest that platelet-derived growth factor (PDGF) might have a role in the development of cervical cancer, therefore it is important to determine whether this growth factor pathway is functional and its targeting with imatinib mesylate leads to growth inhibition of cervical cancer cells., Results: PDGF receptors (PDGFR) and their ligands are frequently expressed in cervical cancer and the majority exhibited a combination of family members co-expression. A number of intronic and exonic variations but no known mutations in the coding sequence of the PDGFRalpha gene were found in cancer cell lines and primary tumors. Growth assays demonstrated that PDGFBB induces growth stimulation that can be blocked by imatinib and that this tyrosine kinase inhibitor on its own inhibits cell growth. These effects were associated with the phosphorylation status of the receptor., Conclusion: The PDGFR system may have a role in the pathogenesis of cervical cancer as their members are frequently expressed in this tumor and cervical cancer lines are growth inhibited by the PDGFR antagonist imatinib.
- Published
- 2006
- Full Text
- View/download PDF
25. Carcinosarcoma of the pancreas arising in a mucinous cystic neoplasm.
- Author
-
Bloomston M, Chanona-Vilchis J, Ellison EC, Ramirez NC, and Frankel WL
- Subjects
- Adenocarcinoma, Mucinous surgery, Aged, Carcinosarcoma surgery, Female, Humans, Pancreatic Neoplasms surgery, Pancreaticoduodenectomy, Adenocarcinoma, Mucinous pathology, Carcinosarcoma pathology, Pancreatic Neoplasms pathology
- Abstract
We report a carcinosarcoma of the pancreas in a 67-year-old woman who presented with nausea, vomiting, and painless jaundice. A work-up demonstrated a well-circumscribed mass in the head of the pancreas. After pylorus-preserving pancreaticoduodenectomy, the tumor was found to be grossly yellow, and it compressed the common bile duct and pancreatic duct. Histological examination of the neoplasm showed a 4.0 x 4.0 x 3.0-cm mucinous cystadenocarcinoma with invasive poorly differentiated carcinoma, well-differentiated squamous cell carcinoma, and sarcomatous stroma invading into the duodenum. There was no evidence of nodal metastasis (pT3N0M0). Immunohistochemical studies showed that the epithelial cells stained positive for cytokeratin 7, cytokeratin AE1/3, cytokeratin monoclonal antibody 5.2, epithelial membrane antigen, M-carcinoembryonic antigen, and low-molecular-weight kininogen, and the sarcomatous component was immunoreactive with vimentin. The patient had an uneventful recovery, but died 4 months later of rapidly progressive metastatic disease to the liver and peritoneum. To the best of our knowledge, this is the second case of carcinosarcoma with invasive epithelial and sarcomatous areas in the background of a mucinous cystic neoplasm of the pancreas.
- Published
- 2006
26. Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma.
- Author
-
Candelaria M, Chanona-Vilchis J, Cetina L, Flores-Estrada D, López-Graniel C, González-Enciso A, Cantú D, Poitevin A, Rivera L, Hinojosa J, de la Garza J, and Dueñas-Gonzalez A
- Abstract
Background: Cisplatin-based chemoradiation is the standard of care for locally advanced cervical cancer patients; however, neoadjuvant modalities are currently being tested. Neoadjuvant studies in several tumor types have underscored the prognostic significance of pathological response for survival; however there is a paucity of studies in cervical cancer investigating this issue., Methods: Four cohorts of patients with locally advanced cervical carcinoma (stages IB2-IIIB); included prospectively in phase II protocols of either neoadjuvant chemotherapy with 1) cisplatin-gemcitabine, 2) oxaliplatin-gemcitabine, 3) carboplatin-paclitaxel or 4) chemoradiation with cisplatin or cisplatin-gemcitabine followed by radical hysterectomy were analyzed for pathological response and survival., Results: One-hundred and fifty three (86%) of the 178 patients treated within these trials, underwent radical hysterectomy and were analyzed. Overall, the mean age was 44.7 and almost two-thirds were FIGO stage IIB. Pathological response rates were as follows: Complete (pCR) in 60 cases (39.2%), Near-complete (p-Near-CR) in 24 (15.6 %) and partial (pPR) in 69 cases (45.1%). A higher proportion rate of pCR was observed in patients treated with chemoradiotherapy (with cisplatin [19/40, 47.5%]; or with cisplatin-gemcitabine [24/41, 58.5%] compared with patients receiving only chemotherapy, 6/23 (26%), 3/8 (37.5%) and 8/41 (19.5%) for cisplatin-gemcitabine, oxaliplatin-gemcitabine and carboplatin-paclitaxel respectively [p = 0.0001]). A total of 29 relapses (18.9%) were documented. The pathological response was the only factor influencing on relapse, since only 4/60 (6.6%) patients with pCR relapsed, compared with 25/93 (26.8%) patients with viable tumor, either pNear-CR or pPR (p = 0.001). Overall survival was 98.3% in patients with pCR versus 83% for patients with either pNear-CR or pPR (p = 0.009)., Conclusion: Complete pathological response but no Near-complete and partial responses is associated with longer survival in cervical cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy.
- Published
- 2006
- Full Text
- View/download PDF
27. eIF4E as a marker for cervical neoplasia.
- Author
-
Matthews-Greer J, Caldito G, de Benedetti A, Herrera GA, Dominguez-Malagon H, Chanona-Vilchis J, and Turbat-Herrera EA
- Subjects
- Biomarkers, Tumor biosynthesis, Eukaryotic Initiation Factor-4E biosynthesis, Humans, Immunohistochemistry, Oncogene Proteins, Viral metabolism, Papillomavirus E7 Proteins, Up-Regulation, Uterine Cervical Dysplasia pathology, Biomarkers, Tumor analysis, Eukaryotic Initiation Factor-4E analysis, Uterine Cervical Dysplasia diagnosis
- Abstract
Eukaryotic translation initiation factor 4E (eIF4E) is upregulated in cancers of the breast and head and neck. The authors have shown that eIF4E is increased in cervical neoplasia and that eIF4E upregulates human papillomavirus (HPV) oncoprotein E7. The aim of this study was to quantitate eIF4E in tissues representing a wide range of cervical pathology. The potential correlation between dysplastic grade or tumor stage with eIF4E upregulation and/or HPV genotype was analyzed for 10 normal, 27 cancer, and 37 dysplasia cases. A progressive increase in eIF4E staining intensity was found with increasing cervical pathology (P < 0.0001). No difference was seen in eIF4E stain intensity by either tumor type--squamous cell cancer (n = 18), adenocarcinoma (n = 4), or other types of cancer (n = 5) (P = 0.97)--or by tumor grade--II (n = 5) versus III (n = 7). Likewise, neither an HPV typing result of HPV 16 (n = 10) versus non-HPV 16 (n = 4) nor single HPV infection (n = 11) versus dual HPV infection (n = 3) significantly altered the eIF4E stain results (P = 0.86 and 0.97, respectively). These results indicate that eIF4E stain intensity may be useful as a marker for cervical neoplasia.
- Published
- 2005
- Full Text
- View/download PDF
28. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes.
- Author
-
Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L, Chavez-Blanco A, Angeles E, Cabrera G, Sandoval K, Trejo-Becerril C, Chanona-Vilchis J, and Duenas-González A
- Subjects
- 5-Methylcytosine pharmacology, Adult, Aged, Binding Sites, Biopsy, Cohort Studies, Cytosine chemistry, DNA genetics, Electrophoresis, Capillary, Female, Humans, Middle Aged, Promoter Regions, Genetic, RNA, Long Noncoding, RNA, Untranslated genetics, Reverse Transcriptase Polymerase Chain Reaction, Vasodilator Agents pharmacology, Cardiovascular Diseases drug therapy, DNA Methylation drug effects, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Hydralazine pharmacology, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms genetics
- Abstract
Background: The antihypertensive compound hydralazine is a known demethylating agent. This phase I study evaluated the tolerability and its effects upon DNA methylation and gene reactivation in patients with untreated cervical cancer., Methods: Hydralazine was administered to cohorts of 4 patients at the following dose levels: I) 50 mg/day, II) 75 mg/day, III) 100 mg/day and IV) 150 mg/day. Tumor biopsies and peripheral blood samples were taken the day before and after treatment. The genes APC, MGMT; ER, GSTP1, DAPK, RARbeta, FHIT and p16 were evaluated pre and post-treatment for DNA promoter methylation and gene expression by MSP (Methylation-Specific PCR) and RT-PCR respectively in each of the tumor samples. Methylation of the imprinted H19 gene and the "normally methylated" sequence clone 1.2 was also analyzed. Global DNA methylation was analyzed by capillary electrophoresis and cytosine extension assay. Toxicity was evaluated using the NCI Common Toxicity Criteria., Results: Hydralazine was well tolerated. Toxicities were mild being the most common nausea, dizziness, fatigue, headache and palpitations. Overall, 70% of the pretreatment samples and all the patients had at least one methylated gene. Rates of demethylation at the different dose levels were as follows: 50 mg/day, 40%; 75 mg/day, 52%, 100 mg/day, 43%, and 150 mg/day, 32%. Gene expression analysis showed only 12 informative cases, of these 9 (75%) re-expressed the gene. There was neither change in the methylation status of H19 and clone 1.2 nor changes in global DNA methylation., Conclusion: Hydralazine at doses between 50 and 150 mg/day is well tolerated and effective to demethylate and reactivate the expression of tumor suppressor genes without affecting global DNA methylation.
- Published
- 2005
- Full Text
- View/download PDF
29. Human papillomavirus typing of rare cervical carcinomas.
- Author
-
Matthews-Greer J, Dominguez-Malagon H, Herrera GA, Unger J, Chanona-Vilchis J, Caldito G, and Turbat-Herrera EA
- Subjects
- Carcinoma pathology, DNA, Viral analysis, Female, Humans, Papillomaviridae isolation & purification, Uterine Cervical Neoplasms pathology, Carcinoma diagnosis, Papillomaviridae classification, Uterine Cervical Neoplasms diagnosis
- Abstract
Context: Most cervical tumors are classified as squamous cell carcinoma or adenocarcinoma, both of which are associated with persistent human papillomavirus (HPV) infection. Although other (rare) types represent less than 5% of all cervical carcinomas, it is necessary that these more unusual tumors be studied in the current era of papillomavirus vaccine development, especially in regions with high incidence of cervical cancer., Objective: To compare papillomavirus types found in histologically rare cervical carcinomas (n = 29) with those types found in common cervical carcinomas (n = 14) archived at the Institute of Cancer in Mexico City, Mexico., Design: Paraffin-embedded tissues were received and sectioned at the Louisiana State University Health Sciences Center at Shreveport. One section for each block was stained and examined by 2 pathologists. Specific histologies were categorized into 2 broad groups: common (squamous cell carcinoma or adenocarcinoma) or rare (adenosquamous, papillary, villoglandular, anaplastic, transitional, spindle, adenoid basal, colloid, neuroendocrine, and glassy cell carcinomas). Papillomavirus typing results were based on Roche Molecular Systems line-blot assay., Results: No significant difference was found for dual HPV types (21% of both groups), positivity for HPV-16 (66% of rare tumors and 71% of common tumors), or absence of HPV types 16 or 18, although the rare cancers had a greater tendency toward more unusual HPV types (8/29 rare tumors and 1/14 common tumors had no HPV- 16 or HPV-18 DNA). Non-HPV-16/18 types found only in rare tumors included HPV types 52, 84, 26, 35, and 58., Conclusions: Rare types of cervical carcinoma also are associated with papillomavirus, most with types similar to those found in common cervical neoplasias.
- Published
- 2004
- Full Text
- View/download PDF
30. Transitional cell carcinoma of the uterine cervix. A report of six cases with clinical, histologic and cytologic findings.
- Author
-
Ortega-Gonzalez P, Chanona-Vilchis J, and Dominguez-Malagon H
- Subjects
- Adult, Aged, Biomarkers, Tumor analysis, Carcinoma, Squamous Cell chemistry, Carcinoma, Squamous Cell diagnosis, Carcinoma, Transitional Cell chemistry, Carcinoma, Transitional Cell diagnosis, Cell Nucleolus pathology, Cell Nucleus pathology, Diagnosis, Differential, Female, Humans, Immunohistochemistry, Keratins analysis, Keratins immunology, Middle Aged, Retrospective Studies, Uterine Cervical Neoplasms chemistry, Uterine Cervical Neoplasms diagnosis, Carcinoma, Transitional Cell pathology, Uterine Cervical Neoplasms pathology
- Abstract
Background: Transitional cell carcinoma of the cervix (TCCC) is a rare neoplasm of recent description. The cytologic characteristics of the tumor have not been published to date. Six cases of TCCC are described, including their clinical, histologic, cytologic and immunohistochemical features., Cases: All cases presented at an advanced clinical stage; two recurred, and one metastasized. Five cases showed a papillary exophytic pattern, and one case showed an "inverted" endophytic pattern similar to that of transitional cell carcinoma of the urothelium (TCCU). The cytokeratin profile was similar to that of squamous cell carcinoma of the cervix (SCCC), positive for CK 7 and negative for CK 20. The cervical smears showed a background that was necrotic or hemorrhagic. The cells with transitional features formed cohesive groups in a multilayered fashion and had an oval or spindle shape with tapered ends. The nuclei were hyperchromatic, with coarse and medium-sized granules that frequently displayed a wrinkled membrane, nuclear grooves and rare pseudoinclusions. The nucleoli were small or absent. Others cells with cytologic characteristics of SCCC were seen in all cases., Conclusion: TCCC is a rare neoplasm that probably represents a subgroup of SCCC. The most frequent histologic pattern is papillary-exophytic, but it can be inverted-endophytic. In cervical smears there are cells with characteristics of regular SCCC and others resembling those of TCCU. A larger number of cases is needed to define the evolution and clinical outcome.
- Published
- 2002
- Full Text
- View/download PDF
31. Large cell calcifying Sertoli cell tumor of the testis: a clinicopathological, immunohistochemical, and ultrastructural study of two cases.
- Author
-
Cano-Valdez AM, Chanona-Vilchis J, and Domínguez-Malagón H
- Subjects
- Adult, Basement Membrane ultrastructure, Cell Nucleolus ultrastructure, Collagen analysis, Fatal Outcome, Humans, Immunohistochemistry, Laminin analysis, Male, S100 Proteins analysis, Sertoli Cell Tumor chemistry, Sertoli Cell Tumor ultrastructure, Testicular Neoplasms chemistry, Testicular Neoplasms ultrastructure, Vimentin analysis, Calcinosis pathology, Sertoli Cell Tumor pathology, Testicular Neoplasms pathology
- Abstract
Large cell calcifying Sertoli cell tumor of the testis (LCCSCT) is a rare tumor that is usually benign and multifocal. It may be associated with hereditary endocrine anomalies such as Carney's and Peutz-Jeghers syndromes. Malignant forms are exceptional. Two cases of LCCSCT, one malignant and one benign are described. Both were composed of cords and trabeculae of large polygonal cells embedded in a myxoid and fibrous stroma with areas of calcification. The malignant tumor showed nuclear atypia, necrosis, and abundant mitoses. The cells were positive for vimentin and S-100 protein, and the intercellular space for laminin and collagen type IV. By electron microscopy, nucleolonemas and multilayered basal lamina were seen. The benign tumor was positive for vimentin and S-100 protein, and ultrastructurally showed less basal lamina.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.